TScan Therapeutics (TCRX) EBT Margin (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed EBT Margin for 6 consecutive years, with 895.09% as the latest value for Q4 2025.
- On a quarterly basis, EBT Margin rose 432581.0% to 895.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 1178.79%, a 331017.0% increase, with the full-year FY2025 number at 1256.81%, up 323214.0% from a year prior.
- EBT Margin was 895.09% for Q4 2025 at TScan Therapeutics, up from 1571.95% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 271.99% in Q4 2023 to a low of 5906.9% in Q2 2024.
- A 5-year average of 1538.57% and a median of 598.29% in 2022 define the central range for EBT Margin.
- Peak YoY movement for EBT Margin: crashed -514308bps in 2024, then skyrocketed 432581bps in 2025.
- TScan Therapeutics' EBT Margin stood at 497.55% in 2021, then fell by -22bps to 604.94% in 2022, then skyrocketed by 55bps to 271.99% in 2023, then plummeted by -1820bps to 5220.9% in 2024, then surged by 83bps to 895.09% in 2025.
- Per Business Quant, the three most recent readings for TCRX's EBT Margin are 895.09% (Q4 2025), 1571.95% (Q1 2025), and 5220.9% (Q4 2024).